usa medical cbd olaj kutyáknak és macskáknak 250 mg/ 30 ml
usa medical kft. - cannabidiol (cbd olaj) - belsoleges emulziós cseppek - carprofen - kutya, macska
usa medical cbd olaj kutyáknak és macskáknak 500 mg/ 30 ml
usa medical kft. - cannabidiol (cbd olaj) - belsoleges emulziós cseppek - canine parvovirus vaccine - kutya, macska
usa medical cbd olaj kutyáknak és macskáknak 1000 mg/ 30 ml
usa medical kft. - cannabidiol (cbd olaj) - belsoleges emulziós cseppek - ketoprofen - kutya, macska
beaphar bio sampon papajával kölyökkutyáknak
beaphar b.v. (hollandia) - kacsapestisvírus duck plague virus, strain jansen, live - sampon - duck enteritis virus vaccine - kutya
fitomune immunerosíto tabletta
vitamed pharma kereskedelmi és szolgáltató kft. - grapefruit seed extract, echinacea purpurea, astragalus gyökér kivonat, homoktövis, (1-3, 1-6) béta-glükán, macskakarom - tabletta - kutya
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunszuppresszánsok - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
ecogreen szilárd sampon grapefruit
urban s.r.l. - chelidonium majus d4, strychnos nux vomica d6, chamomilla recutita d2, citrullus colocynthis d4 - sampon - kutya
glycoflex stage 3 rágótabletta
vetri-science laboratories - c-vitamin, metil-szulfonil-metán, zöldkagyló kivonat, grapefruit seed extract, glukózamin hidroklorid, l-glutation - rágótabletta - kutya
soliris
alexion europe sas - ekulizumab - hemoglobinuria, paroxysmal - immunszuppresszánsok - soliris-kezelés javallt gyermekek kezelésére:paroxizmális éjjeli haemoglobinuria (pnh). bizonyíték a klinikai haszon kimutatható a betegek hemolízis klinikai tünet(ek) jelzi, hogy a magas betegség tevékenység, függetlenül attól, transzfúzió történelem (lásd 5. atipikus hemolitikus urémiás szindróma (ahus). soliris-kezelés javallt felnőtteknél a kezelést:tűzálló generalizált myasthenia gravis (gmg) a betegek, akik anti-acetilkolin receptor (achr) antitest-pozitív (lásd 5. neuromyelitis optica spektrum zavar (nmosd) a betegek, akik anti-aquaporin-4 (aqp4) antitest-pozitív egy lappangó betegség lefolyása.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - szelektív immunszuppresszánsok - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.